To evaluate the efficacy and safety of collagenase clostridium histolyticum (CCH; Xiapex â , Xiaflex â ) in the treatment of Peyronie's disease (PD) using a new modified treatment protocol that aims at reducing the number of injections needed and reducing patient visits, thus reducing the duration and cost of treatment.
Patients and Methods
A prospective study of 53 patients with PD who had treatment with CCH at a single centre using a new modified protocol. The angle of curvature assessment after an intracavernosal injection of prostaglandin E1, the International Index of Erectile Function (IIEF) and Peyronie's Disease Questionnaire (PDQ) were completed at baseline and at week 12 (4 weeks after the last injection). The Global Assessment of Peyronie's disease (GAPD) questionnaire was completed at week 12. Under a penile block of 10 mL plain lignocaine 1%, a total of three intralesional injections of CCH (0.9 mg) were given at 4-weekly intervals using a new modified injection technique. In between injections patients used a combination of home modelling, stretching and a vacuum device on a daily basis to mechanically stretch the plaque. Investigator modelling was not performed.
Results
The mean (range) penile curvature at baseline was 54 (30-90)°. Of the 53 patients in the study, 51 patients (96.2%) had an improvement in the angel of curvature by a mean (range) of 17.36 (0-40)°or 31.4 (0-57)% from baseline after three CCH injections. The final mean (range) curvature was 36.9 (12-75)°(P < 0.001). There was an improvement in each of the IIEF questionnaire domains, all three PDQ domains and the GAPD. CCH was well tolerated by all patients with only mild and transient local adverse events.
Conclusion
The new shortened protocol using CCH treatment is safe, effective, and cost efficient. The results of using only three CCH injections according to this modified protocol are comparable to those of the clinical trials that used eight CCH injections.
Introduction
Peyronie's disease (PD) is a common condition affecting 3-9% of men [1] . It's aetiology is unknown but may be a result of abnormal wound healing due to minor coital trauma in a genetically susceptible individual [2, 3] . It may also be a collagen disease, as it is often associated with the fibromatoses Dupuytren's and Ledderhose disease [4] .
The initial painful inflammation of the tunica albuginea is later replaced with the formation of fibrous plaques, which cause the classical penile deformity, shortening, and a variable degree of erectile dysfunction (ED) [5, 6] . As the condition rarely improves spontaneously, the resultant symptoms can have a significant psychological effect on the patient, with 48% having clinical depression [7] [8] [9] [10] .
Conservative therapy with oral, topical, and intralesional agents; iontophoresis; and extracorporeal shockwave therapy have failed to confirm their efficacy in placebo-controlled trials [11] [12] [13] [14] [15] [16] Collagenase clostridium histolyticum consists of a mixture of purified collagenases (Class I, II), which are naturally produced by the bacterium Clostridium histolyticum. The two collagenases lead to enzymatic disruption of the PD plaque by synergistically hydrolysing the triple helical conformation of Types I and III collagen. CCH also downregulates many of the genes, cytokines, and growth factors that are involved in the pathogenesis of PD. CCH was not found to cause damage to nerves, arteries and large veins in vitro, as it does not affect Type IV collagen; however, it may lyse collagen Type IV in small veins [17] .
The clinical safety and efficacy of CCH in men with PD was shown in two large phase III randomised, double-blind, placebo-controlled studies; the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I and II (IMPRESS I and II) [18, 19] . This resulted in a 17°or 34% reduction in curvature and an improvement in the patients' symptoms scores. The protocol for use of CCH included patients with a curvature of 30-90°in a dorsal or lateral direction, absence of significant plaque calcification, and a disease duration of >1 year. Each patient had a total of eight injections split into four cycles of two injections given 24-72 h apart and at 6-weekly intervals.
The IMPRESS studies also included modelling of the penis to improve the curvature after each cycle of injections. This is not a new concept, as traction therapy of the penis is a recognised treatment to help straighten the curvature, either with a stretcher or a vacuum device [20, 21] .
The aim of the present study was to evaluate the efficacy and safety of CCH in the treatment of PD using a new modified treatment protocol that aimed to reduce the number of injections and patient visits needed, thus reducing the cost and duration of treatment.
Patients and Methods
This is a prospective evaluation of patients with PD who had treatment with CCH at a single centre using a new modified protocol. All patients had either a dorsal or lateral curvature of ≥30°, with stable disease that had been present for ≥12 months, without any change in the deformity for ≥3 months [16] . Patients with active disease, complete plaque calcification, ventral curvature, or ED not responsive to oral phosphodiesterase type 5 inhibitors (PDE5Is) or intracavernosal injections of prostaglandin E1 (PGE1), were excluded.
Under a penile block of 10 mL plain lignocaine 1%, a total of three intralesional injections of CCH (0.9 mg) were given at 4-weekly intervals. The whole vial was used and injected in multiple positions at the apex of the curvature in the flaccid penis. Penile compression was not applied and antiinflammatory medication used for 2-3 days. Patients were instructed to keep the penis elevated and to avoid sexual intercourse for 2 weeks.
In between injections patients used a combination of home modelling, stretching, and a vacuum device on a daily basis to mechanically stretch the plaque. Home modelling was performed 24 h after the CCH injection, with the patients instructed to attempt to gently straighten the erect penis ( Fig. 1 ). Stretching exercises consisted of a gradual stretch of the flaccid penis for 60 s each time they visited the urinal. Vacuum pump therapy was started 2-3 days after the CCH injection, once the swelling had subsided using the SOMAcorrect device (iMEDicare Ltd, Watford, UK). The patients used a vacuum device without the constriction ring, twice daily to mechanically stretch the penis. The cylinder was applied to the penis and slowly inflated until the penis was erect and maintained in this position for 1-2 min. Patients were advised to pump slowly and gently and not to over pump the penis to avoid complications. The vacuum was then released to allow the erection to subside and the process was repeated again five times. Physician plaque modelling was not performed.
The stretched penile length was measured in centimetres from the symphysis pubis by compressing the fad pad to the tip of the glans with the penis in full stretch using a ruler, the angle of curvature was assessed during erection after an intracavernosal injection of PGE1 using a goniometer protractor, the International Index of Erectile Function (IIEF) and the Peyronie's Disease Questionnaire (PDQ) were completed at baseline and at week 12 (4 weeks after the last injection). The Global Assessment of Peyronie's disease (GAPD) questionnaire was also completed at week 12. All patients were advised on the importance of adhering to the home stretching exercises and this was confirmed at each visit.
The distribution of all variables was tested using the ShapiroWilk normality test, and graphically with a q-q plot. A paired t-test was used to compare mean curvature, stretched penile length, questionnaires' domains, before and after the treatment. The IBM Statistical Package for the Social Sciences (SPSS â version 23.0; IBM Corp., Armonk, NY, USA) was used for the statistical analyses.
Results
In all, 53 patients completed treatment with the modified protocol with each receiving three CCH injections on a 4-weekly basis. The mean (range) patient age was 54 (35-72) years and duration of PD was 22.8 (12-120) months (Table 1) . ED was present in 21 patients (40%); all of whom were able achieve penetrative intercourse with the help of 'on-demand' PDE5Is. The mean (range) penile curvature at baseline was 54 (30-90)°dorsal, lateral or dorsolateral in direction (Fig. 2) . Of the 53 patients in the study, 51 patients (96.2%) had an improvement in the angel of curvature by a mean (range) of 17.36 (0-40)°or 31.4 (0-57)% from baseline after three CCH injections. The final mean (range) curvature was 36.9 (12-75)°(P < 0.001; Fig. 3 ). Improvement was seen in all curvature groups, irrespective of whether there was mild or severe penile curvature at baseline (Fig. 4) .
The mean stretched penile length improved from 12.9 to 13.3 cm (P < 0.01). The presence of partial plaque calcification did not influence the outcome (P = 0.2).
There was an improvement in all IIEF questionnaire domains, which was statistically significant for the 'Erectile Function', 'Intercourse Satisfaction', and 'Overall Satisfaction' domains (from 20.9 to 23.75, P < 0.001; from 7.7 to 9.4, P < 0.01; and from 5.0 to 6.8, P < 0.001, respectively; Fig. 5 ).
There was also an improvement in all the PDQ domains, which was statistically significant for 'Pain' and 'Bother' (from 4.5 to 2.8, P < 0.05 and from 8.9 to 6.1, P < 0.01, respectively; Fig. 6 ). According to the GAPD questionnaire, most patients (45 patients; 85%) reported a subjective curvature improvement, six patients felt no change, and two patients felt that the curvature was a little worse (Fig. 7) .
Collagenase clostridium histolyticum was well tolerated by all patients with only mild and transient penile swelling and bruising occurring in all participants. Two patients developed a penile haematoma, which was managed conservatively in one patient and by aspiration in the other. Five more patients developed small penile haematomas from the vacuum pump, which were managed conservatively. Two patients developed small cutaneous blisters, which were managed conservatively. There were no systemic adverse events ( Table 2) .
Discussion
Collagenase clostridium histolyticum (Xiapex) is a licenced product for the treatment of PD and has shown to be safe and effective in two large phase III randomised, double-blind, placebo-controlled studies (IMPRESS I and II) [18, 19] . The protocol used in those trials and recommended for use involves up to four treatment cycles separated by 6 weeks; each treatment cycle consists of two CCH injections (0.58 mg) separated by 1-3 days and injected into the plaque at the point of maximal penile curvature in the flaccid state. At 1-3 days after the second injection, physician plaque modelling is performed by stretching and bending the penis in an opposite direction to the point of maximum curvature. In between treatment cycles, patients performed penile stretching and modelling exercises at home.
The present article describes a new modified shortened protocol based on the authors experience as investigators for the CCH UK clinical trials. In this modified protocol, only one injection (0.9 mg; the whole vial) is given per cycle compared to two injections per cycle (0.58 mg each) in the clinical trial protocol. The single injection of a higher concentration allows for a better distribution of the drug over a wider area of the apex of the curvature. Also, as all patients develop an inflammatory swelling after each injection, palpation of the plaque becomes difficult and so a second injection after 1-3 days in not only inaccurate but makes the inflammatory reaction much worse. A single injection is therefore of benefit with regards to accuracy and safety. Vacuum pump therapy has been shown to be safe and effective in PD [20] and was therefore incorporated in our present protocol instead of physician modelling, which the patients find uncomfortable and adds an extra patient visit. Overall the modified protocol involves four patient visits over a 12-week period, including the assessments before and after treatment, as opposed to 14 patient visits over a 24 week period for the classic protocol. The modified protocol uses three CCH injections vs eight CCH injections for the classic protocol (Fig. 8) . The cost savings are therefore obvious.
The results of the modified protocol show a mean curvature reduction of -17.36°or À31.42% from baseline, which is comparable with the results described by the IMPRESS trials that show a mean curvature reduction of À17°or À34% from baseline.
The modified protocol was not associated with any significant side-effects than were not anticipated. All sideeffects were local and transient, mainly in the form of swelling and bruising. None of the patients developed a corporal rupture. In common with the IMPRESS data, the results of the present study show that the improvement in penile curvature is also associated with an improvement in the stretched penile length, the IIEF questionnaire domains, and an improvement in the PDQ 'Bother', 'Pain' and 'Physical and Psychological' symptom domains.
The present study shows that all degrees of penile curvature can benefit from CCH treatment (Fig. 4) . The GAPD questionnaire is a single question that asks patients how they felt the treatment changed their disease; our present results show that most patients considered that there was an improvement in penile curvature in response to treatment (Fig. 7) . Although patients will still have a residual curvature after treatment, most patients are happy if the improvement allows penetrative intercourse without the need for a surgical correction. Furthermore, as only three CCH injections are used as opposed to eight, more CCH may be administrated to achieve further curvature reduction, if there is an initial favourable response. This will also prevent patients having unnecessary injections, as if there is no response after three injections then it is pointless to continue with this form of therapy.
Another benefit is downgrading of the surgical management by reducing the advanced curvature to a more manageable lesser curvature. This would allow a conversion of a grafting operation to a plication, thus reducing postoperative complications, especially penile shortening and ED [22] .
Although the results of the present study showed statistical significance, the sample size was relatively small and more highly powered studies are recommended to further establish the true therapeutic efficacy. The sample size in the present study was that of convenience and included all the patients attending our centre, who fulfilled the inclusion criteria at the time of the study. The limited sample size has precluded us from including a control group when designing the methodology, but this would not be an issue with future studies with larger sample sizes.
Furthermore, the results of our present study are limited to our centre and future studies should ideally be conducted on a multicentre level, so as to infer the results onto more diverse patient populations.
In conclusion, the new shortened protocol using CCH treatment is safe, effective, and cost efficient. The results of using only three CCH injections according to this modified protocol are comparable to those of the classical eight CCH injections.
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